Dan Hemming is an associate in the Los Angeles office of Latham & Watkins and a member of the Litigation & Trial Department.
As a member of the Intellectual Property Litigation Practice, Dan focuses on high-stakes patent litigation in the district court. He has experience spanning all phases of litigation, including pre-suit diligence, fact and expert discovery, claim construction, dispositive motions, trial, and post-trial briefing.
Dan’s work focuses on life sciences technologies. He has represented industry-leading companies in patent cases related to various technologies, including drug compounds and formulations, antibody-drug conjugates, and gene editing.
Dan received his JD from Georgetown University Law Center, where he served as an executive editor for the Journal of Law and Public Policy. He also holds a BS in molecular, cell, and developmental biology from UCLA.
Experience
Dan’s experiences includes representing:
Sarepta in a patent jury trial relating to exon-skipping antisense oligonucleotides for Duchenne Muscular Dystrophy
AbbVie in a Hatch-Waxman litigation involving Rinvoq®
Qualifications
Bar Qualification
California
Education
JD, Georgetown University Law Center, 2023
BS in Molecular, Cell, and Developmental Biology, University of California, Los Angeles, 2019
A Latham team led by David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Covington, for their outstanding representation of AbbVie in securing the latest of five patent litigation settlements with generic makers that are set to protect its blockbuster immunology drug Rinvoq until 2037.
A Latham team led by Mike Morin and David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Finnegan, for their outstanding defense against a US$290 million patent infringement claim and securing a US$116 million award on behalf of Sarepta Therapeutics, in a one-week timed trial in Delaware.
Latham secured a US$115 million verdict for Sarepta Therapeutics and the University of Western Australia in a patent infringement claim against Nippon Shinyaku.
A Delaware federal jury has determined a Japanese pharmaceutical company owes a Massachusetts-based drug developer more than US$115 million for patent infringement, marking a win for Latham & Watkins and Finnegan, who represented Sarepta Therapeutics.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.